4.34
-1.36%
Close of 20 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
Price performance
Chart by TradingView, with its own licensed prices
- Market value
- $60.3m
- Last close × shares
- Volume
- 8.9k
- Shares, 20 Nov 2026
About Champions Oncology
From its filings with the US Securities and Exchange Commission
Champions Oncology is based in Baltimore, Maryland and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker CSBR. The SEC classifies its business as biological products, (no diagnostic substances). In the fiscal year to 30 April 2026, it reported revenue of $59.4m and a net loss of $1.2m. At that date it held total assets of $27.0m and shareholders' equity of $3.9m.
We are a technology-enabled research organization engaged in creating technology solutions to be utilized in drug discovery and development. Our research center operates in both regulatory and non-regulatory environments and consists of a comprehensive set of computational and experimental research platforms. Our pharmacology, biomarker, and data platforms are designed to facilitate drug discovery and development at lower costs and increased speeds.
At the core of our research platforms is our unique, proprietary bank of Patient Derived Xenograft (PDX) models. This preeminent bank of PDX models is deployed into advanced in vivo and ex vivo pharmacology platforms, providing an enhanced level of insight into therapeutic programs. We currently have approximately 1,500 PDX Models in our TumorBank that we believe reflect the characteristics of patients who enroll in clinical trials (late stage, pretreated and metastatic). This characteristic of our TumorBank is an important differentiator to other established PDX banks. We implant and expand these tumors in mice, which allows for future studies and additional characterization of the tumor. Additional analytical and pharmacology experimental platforms are also available to augment the information gained from studies performed.
Quoted from its 10-K, filed 27 Jul 2026. Read the filing on SEC.gov ↗
How it makes its money
Revenue, year to 30 Apr 2025
- Pharmacology services $48.6m · 85.3%
- TOS data license revenue $4.7m · 8.2%
- Other TOS revenue $3.7m · 6.5%
Latest on Champions Oncology
Our reporting
We have not reported on Champions Oncology yet.
Next results
Due on 15 Dec 2026. Analysts expect earnings of 0.02 a share.
Other Health Care listings
Scenario calculator
Try your own numbers. This is arithmetic, not a forecast.
Gain or loss
Return
Leaves out fees, taxes and financing.
Frequently asked questions
What is Champions Oncology's ticker?
Champions Oncology trades as CSBR on its US listing, under ISIN US15870P3073.
What was Champions Oncology's last closing price?
4.34 on 20 Nov 2026. The figure is in USD and is never converted.
When does Champions Oncology next report results?
Results are expected on 15 Dec 2026, according to our data supplier.
Sources and methodology
- Chart
- TradingView
- Close and company data
- SEC filings and our data supplier
- News
- Our reporting
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.